



PATENT  
Docket No. 500862001500  
Clt Ref: REDC-1511

#11  
Statements re  
Seq. Disch  
3/17/03

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on February 19, 2003.

LILIA OLSEN

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Dominique P. BRIDON, et al.

Serial No.: 09/657,336

Filing Date: September 7, 2000

For: LONG LASTING FUSION PEPTIDE  
INHIBITORS OF VIRAL INFECTION

Examiner: J. Parkin

Group Art Unit: 1648

RECEIVED  
MAR 10 2003  
TECH CENTER 1600/2900

**STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825**

BOX SEQUENCE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

The undersigned hereby states that the content of the attached papers and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

In the unlikely event that the Patent Office determines that an extension and/or other relief is required as a result of this statement, applicants petition for any required relief including

extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due to our **Deposit account no. 03-1952** referencing 500862001500. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: February 19, 2003

By: Michael R Ward  
Michael R. Ward  
Registration No. 38,651

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522



1648  
Box 569

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/657,336
Filing Date	September 7, 2000
First Named Inventor	Dominique P. BRIDON
Group Art Unit	1648
Examiner Name	J. Parkin
Attorney Docket No.	500862001500

Total Number Of Pages In This Submission

267

## ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form - 1 pg IN DUPL	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input checked="" type="checkbox"/> Response to Notice to Comply, Paper 9 and Amended Election to Restriction Requirement - 18 pgs (not including INSERTS)	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Extension of Time Request - 1 pg	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	RETURN RECEIPT POSTCARD
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	1. COPY of Notice as required - 1 pg
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	2. INSERT: Replacement pages to Specification - pages 4, 5, 23 and 137-170;
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		3. Sequence List:
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		Statement in Support - 2 pgs
		Paper copy - 164 pgs
		CRF - 1 disk

## SIGNATURE OF APPLICANT, ATTORNEY OR AGENT


Firm or Individual Name	MORRISON & FOERSTER LLP 425 Market Street, San Francisco, CA 94105-2842 MICHAEL R. WARD (Reg No. 38,651)
Signature	Michael R Ward
Date	February 19, 2003

## CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on February 19, 2003.

LITA OLSEN

RECEIVED  
MAR 10 2003  
TECH CENTER 1600/2918



RECEIVED

MAR 10 2003

09/657,336 TECH CENTER 1600/2900 Application No.: 09/657,336

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: *Applicants are reminded that all sequences governed by 37 CFR 1.821-1.825 including those present in Tables or Figures must also refer to the relevant SEQ. ID. NO.*
- Applicant Must Provide:**
- ☒ An initial ~~or substitute~~ computer readable form (CRF) copy of the "Sequence Listing".
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**